Do analysts prefer AADI or BRNS?

Barinthus Biotherapeutics has a consensus target price of $4.00, indicating a potential upside of 505.51%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Barinthus Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is KLRS or BRNS more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -72.78% -43.49% Barinthus Biotherapeutics N/A -63.83% -48.77%

Is PMN or BRNS more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -237.99% -151.04% Barinthus Biotherapeutics N/A -63.83% -48.77%

Barinthus Biotherapeutics (BRNS) Competitors

$0.66 -0.04 (-5.63%)

Closing price 03:59 PM Eastern

Extended Trading

$0.67 +0.01 (+2.03%)

As of 07:58 PM Eastern

Compare

BRNS vs. AADI, KLRS, ATRA, VRCA, and PMN

Should you buy Barinthus Biotherapeutics stock or one of its competitors? MarketBeat compares Barinthus Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Barinthus Biotherapeutics include Aadi Bioscience (AADI), Kalaris Therapeutics (KLRS), Atara Biotherapeutics (ATRA), Verrica Pharmaceuticals (VRCA), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry.

How does Barinthus Biotherapeutics compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Aadi Bioscience has higher revenue and earnings than Barinthus Biotherapeutics. Aadi Bioscience is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.10	-$65.76M	-$2.35	N/A
Barinthus Biotherapeutics	$14.97M	1.80	-$66.43M	-$1.29	N/A

Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.4, suggesting that its share price is 140% less volatile than the broader market.

In the previous week, Barinthus Biotherapeutics had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for Barinthus Biotherapeutics and 0 mentions for Aadi Bioscience. Barinthus Biotherapeutics' average media sentiment score of 0.43 beat Aadi Bioscience's score of 0.00 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Barinthus Biotherapeutics	Neutral

Barinthus Biotherapeutics has a consensus target price of $4.00, indicating a potential upside of 505.51%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Barinthus Biotherapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Barinthus Biotherapeutics' return on equity of -63.83% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Summary

Barinthus Biotherapeutics beats Aadi Bioscience on 10 of the 16 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Kalaris Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.4, meaning that its stock price is 140% less volatile than the broader market.

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by company insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Barinthus Biotherapeutics' return on equity of -63.83% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Kalaris Therapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Barinthus Biotherapeutics	$14.97M	1.80	-$66.43M	-$1.29	N/A

Kalaris Therapeutics presently has a consensus target price of $15.60, indicating a potential upside of 269.67%. Barinthus Biotherapeutics has a consensus target price of $4.00, indicating a potential upside of 505.51%. Given Barinthus Biotherapeutics' higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Kalaris Therapeutics and Kalaris Therapeutics both had 2 articles in the media. Kalaris Therapeutics' average media sentiment score of 0.94 beat Barinthus Biotherapeutics' score of 0.43 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Kalaris Therapeutics	Positive
Barinthus Biotherapeutics	Neutral

Summary

Kalaris Therapeutics beats Barinthus Biotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Atara Biotherapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.4, meaning that its share price is 140% less volatile than the broader market.

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Atara Biotherapeutics currently has a consensus price target of $9.50, indicating a potential downside of 14.95%. Barinthus Biotherapeutics has a consensus price target of $4.00, indicating a potential upside of 505.51%. Given Barinthus Biotherapeutics' higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Barinthus Biotherapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Barinthus Biotherapeutics' return on equity of -63.83% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Atara Biotherapeutics has higher revenue and earnings than Barinthus Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.83	$32.69M	-$0.67	N/A
Barinthus Biotherapeutics	$14.97M	1.80	-$66.43M	-$1.29	N/A

In the previous week, Atara Biotherapeutics and Atara Biotherapeutics both had 2 articles in the media. Atara Biotherapeutics' average media sentiment score of 0.93 beat Barinthus Biotherapeutics' score of 0.43 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Atara Biotherapeutics	Positive
Barinthus Biotherapeutics	Neutral

Summary

Atara Biotherapeutics beats Barinthus Biotherapeutics on 8 of the 13 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Verrica Pharmaceuticals presently has a consensus target price of $14.50, suggesting a potential upside of 123.08%. Barinthus Biotherapeutics has a consensus target price of $4.00, suggesting a potential upside of 505.51%. Given Barinthus Biotherapeutics' higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Verrica Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.4, suggesting that its stock price is 140% less volatile than the broader market.

Verrica Pharmaceuticals has higher revenue and earnings than Barinthus Biotherapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	3.14	-$17.89M	-$1.03	N/A
Barinthus Biotherapeutics	$14.97M	1.80	-$66.43M	-$1.29	N/A

Barinthus Biotherapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Barinthus Biotherapeutics' return on equity of -63.83% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 2 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 0.97 beat Barinthus Biotherapeutics' score of 0.43 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Positive
Barinthus Biotherapeutics	Neutral

Summary

Verrica Pharmaceuticals beats Barinthus Biotherapeutics on 11 of the 15 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Promis Neurosciences?

Promis Neurosciences (NASDAQ:PMN) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Promis Neurosciences has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.4, suggesting that its share price is 140% less volatile than the broader market.

50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 1.5% of Promis Neurosciences shares are held by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Barinthus Biotherapeutics' return on equity of -63.83% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Promis Neurosciences has higher earnings, but lower revenue than Barinthus Biotherapeutics. Promis Neurosciences is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Barinthus Biotherapeutics	$14.97M	1.80	-$66.43M	-$1.29	N/A

Promis Neurosciences currently has a consensus price target of $26.50, suggesting a potential upside of 146.51%. Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 505.51%. Given Barinthus Biotherapeutics' higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Promis Neurosciences and Promis Neurosciences both had 2 articles in the media. Promis Neurosciences' average media sentiment score of 0.94 beat Barinthus Biotherapeutics' score of 0.43 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Promis Neurosciences	Positive
Barinthus Biotherapeutics	Neutral

Summary

Promis Neurosciences and Barinthus Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Barinthus Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRNS vs. The Competition

Export

Metric	Barinthus Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$28.59M	$3.62B	$6.85B	$12.20B
Dividend Yield	N/A	2.21%	2.66%	6.22%
P/E Ratio	-0.51	20.93	26.04	24.36
Price / Sales	1.80	342.90	550.17	103.06
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	0.36	8.71	10.98	6.49
Net Income	-$66.43M	$23.87M	$3.57B	$336.61M
7 Day Performance	-4.95%	4.23%	3.06%	0.90%
1 Month Performance	-3.28%	1.71%	0.72%	-0.36%
1 Year Performance	-28.97%	69.92%	36.82%	31.26%

Barinthus Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRNS Barinthus Biotherapeutics	2.1012 of 5 stars	$0.66 -5.6%	$4.00 +505.5%	-24.7%	$28.59M	$14.97M	N/A	107	Short Interest Increase Gap Up
AADI Aadi Bioscience	N/A	$4.37 -2.0%	N/A	+115.5%	$107.93M	$25.07M	N/A	40
KLRS Kalaris Therapeutics	3.9898 of 5 stars	$4.40 -1.6%	$15.60 +254.5%	+64.9%	$106.35M	N/A	N/A	110
ATRA Atara Biotherapeutics	0.9724 of 5 stars	$10.55 -5.5%	$9.50 -10.0%	+32.0%	$100.55M	$120.77M	N/A	330	Analyst Upgrade
VRCA Verrica Pharmaceuticals	3.2257 of 5 stars	$5.85 +3.5%	$14.50 +147.9%	+30.9%	$97.06M	$35.58M	N/A	40	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRNS) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. AADI, KLRS, ATRA, VRCA, and PMN

How does Barinthus Biotherapeutics compare to Aadi Bioscience?

Summary

How does Barinthus Biotherapeutics compare to Kalaris Therapeutics?

Summary

How does Barinthus Biotherapeutics compare to Atara Biotherapeutics?

Summary

How does Barinthus Biotherapeutics compare to Verrica Pharmaceuticals?

Summary

How does Barinthus Biotherapeutics compare to Promis Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. AADI, KLRS, ATRA, VRCA, and PMN

How does Barinthus Biotherapeutics compare to Aadi Bioscience?

Which has better earnings & valuation, AADI or BRNS?

Which has more risk & volatility, AADI or BRNS?

Does the media favor AADI or BRNS?

Do analysts prefer AADI or BRNS?

Do institutionals & insiders have more ownership in AADI or BRNS?

Is AADI or BRNS more profitable?

Summary

How does Barinthus Biotherapeutics compare to Kalaris Therapeutics?

Which has more risk & volatility, KLRS or BRNS?

Do insiders & institutionals believe in KLRS or BRNS?

Is KLRS or BRNS more profitable?

Which has higher valuation and earnings, KLRS or BRNS?

Do analysts recommend KLRS or BRNS?

Does the media favor KLRS or BRNS?

Summary

How does Barinthus Biotherapeutics compare to Atara Biotherapeutics?

Which has more volatility & risk, ATRA or BRNS?

Do insiders and institutionals believe in ATRA or BRNS?

Do analysts recommend ATRA or BRNS?

Is ATRA or BRNS more profitable?

Which has preferable earnings & valuation, ATRA or BRNS?

Does the media favor ATRA or BRNS?

Summary

How does Barinthus Biotherapeutics compare to Verrica Pharmaceuticals?

Do analysts prefer VRCA or BRNS?

Do institutionals and insiders have more ownership in VRCA or BRNS?

Which has more risk & volatility, VRCA or BRNS?

Which has higher valuation and earnings, VRCA or BRNS?

Is VRCA or BRNS more profitable?

Does the media prefer VRCA or BRNS?

Summary

How does Barinthus Biotherapeutics compare to Promis Neurosciences?

Which has more volatility & risk, PMN or BRNS?

Do institutionals & insiders have more ownership in PMN or BRNS?

Is PMN or BRNS more profitable?

Which has preferable earnings & valuation, PMN or BRNS?

Do analysts prefer PMN or BRNS?

Does the media favor PMN or BRNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools